<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">31187587</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2162-3279</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Brain and behavior</Title>
          <ISOAbbreviation>Brain Behav</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998-2008, 2007-2014).</ArticleTitle>
        <Pagination>
          <StartPage>e01338</StartPage>
          <MedlinePgn>e01338</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e01338</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/brb3.1338</ELocationID>
        <Abstract>
          <AbstractText>Epidemiological studies of the uncommon disorder neuromyelitis optica spectrum disorder (NMOSD) may be difficult to interpret because of the evolving nature of diagnostic criteria, differences in the definition and accuracy of NMOSD diagnosis, the completeness of case ascertainment, and variability in assays for the disease-specific biomarker aquaporin-4 (AQP4)-IgG. A sub-group of patients with the clinical syndrome NMOSD lack detectable AQP4-IgG and in these cases an accurate diagnosis requires precise diagnostic algorithms and longitudinal follow-up. Consecutive sets of criteria for NMO/NMOSD have been introduced during the two last decades. Such criteria need validation in different populations. Detection of other autoantibodies, such as IgG specific for myelin oligodendrocyte glycoprotein or for glial fibrillary acidic protein in a sub-group of AQP4-IgG-negative NMOSD patients, has improved over the past decade and may lead to overlap of the clinical syndromes/phenotypes. This review begins by summarizing current knowledge on the widening clinical spectrum of NMOSD. Subsequently, we describe two epidemiological studies from Denmark carried out in two different decades (1998-2008 and 2007-2014) and comment on the differences in study design, patient ascertainment, and interpretation of results. These factors may explain some of the observed differences, reflecting the complexity and providing a clear example of this development.</AbstractText>
          <CopyrightInformation>© 2019 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Asgari</LastName>
            <ForeName>Nasrin</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0001-8551-0947</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Regional Health Research, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lillevang</LastName>
            <ForeName>Soeren T</ForeName>
            <Initials>ST</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skejoe</LastName>
            <ForeName>Hanne P B</ForeName>
            <Initials>HPB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Aleris-Hamlet Hospital, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kyvik</LastName>
            <ForeName>Kirsten O</ForeName>
            <Initials>KO</Initials>
            <AffiliationInfo>
              <Affiliation>OPEN (Odense Patient data Explorative Network), Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>06</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Brain Behav</MedlineTA>
        <NlmUniqueID>101570837</NlmUniqueID>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="N">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">epidemiology</Keyword>
        <Keyword MajorTopicYN="Y">neuromyelitis optica spectrum disease</Keyword>
      </KeywordList>
      <CoiStatement>None.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31187587</ArticleId>
        <ArticleId IdType="pmc">PMC6625475</ArticleId>
        <ArticleId IdType="doi">10.1002/brb3.1338</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>

Asgari, N.
, 
Flanagan, E. P.
, 
Fujihara, K.
, 
Kim, H. J.
, 
Skejoe, H. P.
, 
Wuerfel, J.
, … 
Weinshenker, B. G.
 (2017). Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurology—neuroimmunology Neuroinflammation, 4(4), e343
10.1212/NXI.0000000000000343
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000343</ArticleId>
            <ArticleId IdType="pmc">PMC5400808</ArticleId>
            <ArticleId IdType="pubmed">28451627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Asgari, N.
, 
Lillevang, S. T.
, 
Skejoe, H. P. B.
, 
Falah, M.
, 
Stenager, E.
, &amp; 
Kyvik, K. O.
 (2011). A population‐based study of neuromyelitis optica in Caucasians. Neurology, 76(18), 1589–1595. 10.1212/WNL.0b013e3182190f74
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182190f74</ArticleId>
            <ArticleId IdType="pmc">PMC3269768</ArticleId>
            <ArticleId IdType="pubmed">21536639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Asgari, N.
, 
Nielsen, C.
, 
Stenager, E.
, 
Kyvik, K. O.
, &amp; 
Lillevang, S. T.
 (2012). HLA, PTPN22 and PD‐1 associations as markers of autoimmunity in neuromyelitis optica. Multiple Sclerosis Journal, 18(1), 23–30. 10.1177/1352458511417480
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458511417480</ArticleId>
            <ArticleId IdType="pubmed">21908482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Asgari, N.
, 
Skejoe, H. P.
, &amp; 
Lennon, V. A.
 (2013). Evolution of longitudinally extensive transverse myelitis in an aquaporin‐4 IgG‐positive patient. Neurology, 81(1), 95–96. 10.1212/WNL.0b013e318297ef07
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e318297ef07</ArticleId>
            <ArticleId IdType="pmc">PMC3770200</ArticleId>
            <ArticleId IdType="pubmed">23817516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Asgari, N.
, 
Skejoe, H. P. B.
, 
Lillevang, S. T.
, 
Steenstrup, T.
, 
Stenager, E.
, &amp; 
Kyvik, K. O.
 (2013). Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): A population‐based, descriptive study. BMC Neurology, 13, 33
10.1186/1471-2377-13-33
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2377-13-33</ArticleId>
            <ArticleId IdType="pmc">PMC3622587</ArticleId>
            <ArticleId IdType="pubmed">23566260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Bennett, J. L.
, 
de Seze, J.
, 
Lana‐Peixoto, M.
, 
Palace, J.
, 
Waldman, A.
, 
Schippling, S.
, … 
Paul, F.
 (2015). Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Multiple Sclerosis Journal, 21(6), 678–688. 10.1177/1352458514567216
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514567216</ArticleId>
            <ArticleId IdType="pmc">PMC4425816</ArticleId>
            <ArticleId IdType="pubmed">25662342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Borisow, N.
, 
Mori, M.
, 
Kuwabara, S.
, 
Scheel, M.
, &amp; 
Paul, F.
 (2018). Diagnosis and treatment of NMO spectrum disorder and MOG‐encephalomyelitis. Frontiers in Neurology, 9, 888
10.3389/fneur.2018.00888
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.00888</ArticleId>
            <ArticleId IdType="pmc">PMC6206299</ArticleId>
            <ArticleId IdType="pubmed">30405519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Cacciaguerra, L.
, 
Meani, A.
, 
Mesaros, S.
, 
Radaelli, M.
, 
Palace, J.
, 
Dujmovic‐Basuroski, I.
, … 
Rocca, M. A.
 (2019). Brain and cord imaging features in neuromyelitis optica spectrum disorders. Annals of Neurology, 10.1002/ana.25411
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.25411</ArticleId>
            <ArticleId IdType="pubmed">30635936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Dale, G. H.
, 
Svendsen, K. B.
, 
Gjelstrup, M. C.
, 
Christensen, T.
, 
Houen, G.
, 
Nielsen, E.
, … 
Petersen, T.
 (2018). Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. Acta Neurologica Scandinavica, 10.1111/ane.12903
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ane.12903</ArticleId>
            <ArticleId IdType="pubmed">29359475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

de Seze, J.
, 
Arndt, C.
, 
Jeanjean, L.
, 
Zephir, H.
, 
Blanc, F.
, 
Labauge, P.
, … 
Speeg, C.
 (2008). Relapsing inflammatory optic neuritis: Is it neuromyelitis optica?
Neurology, 70(22), 2075–2076. 10.1212/01.wnl.0000313375.20123.25
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000313375.20123.25</ArticleId>
            <ArticleId IdType="pubmed">18505981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
E. D.
(1894). Myelite subaigue compliquee de neurite optique. Bull Med, 8, 1033–1034.</Citation>
        </Reference>
        <Reference>
          <Citation>

Flanagan, E. P.
, 
Cabre, P.
, 
Weinshenker, B. G.
, 
Sauver, J. S.
, 
Jacobson, D. J.
, 
Majed, M.
, … 
Pittock, S. J.
 (2016). Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum. Annals of Neurology, 10.1002/ana.24617
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24617</ArticleId>
            <ArticleId IdType="pmc">PMC4988933</ArticleId>
            <ArticleId IdType="pubmed">26891082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Flanagan, E. P.
, 
Hinson, S. R.
, 
Lennon, V. A.
, 
Fang, B.
, 
Aksamit, A. J.
, 
Morris, P. P.
, … 
McKeon, A.
 (2017). Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Annals of Neurology, 81(2), 298–309. 10.1002/ana.24881
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24881</ArticleId>
            <ArticleId IdType="pubmed">28120349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Flanagan, E. P.
, &amp; 
Weinshenker, B. G.
 (2014). Neuromyelitis optica spectrum disorders. Current Neurology and Neuroscience Reports, 14(9), 483
10.1007/s11910-014-0483-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11910-014-0483-3</ArticleId>
            <ArticleId IdType="pubmed">25027264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Flanagan, E. P.
, 
Weinshenker, B. G.
, 
Krecke, K. N.
, 
Lennon, V. A.
, 
Lucchinetti, C. F.
, 
McKeon, A.
, … 
Pittock, S. J.
 (2015). Short myelitis lesions in aquaporin‐4‐IgG‐positive neuromyelitis optica spectrum disorders. JAMA Neurology, 72(1), 81–87. 10.1001/jamaneurol.2014.2137
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.2137</ArticleId>
            <ArticleId IdType="pmc">PMC4552048</ArticleId>
            <ArticleId IdType="pubmed">25384099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Gahlen, A.
, 
Trampe, A.‐K.
, 
Haupeltshofer, S.
, 
Ringelstein, M.
, 
Aktas, O.
, 
Berthele, A.
, … 
Kleiter, I.
 (2017). Aquaporin‐4 antibodies in patients treated with natalizumab for suspected MS. Neurology—neuroimmunology Neuroinflammation, 4(4), e363
10.1212/NXI.0000000000000363
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000363</ArticleId>
            <ArticleId IdType="pmc">PMC5473957</ArticleId>
            <ArticleId IdType="pubmed">28642888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Gold, S. M.
, 
Willing, A.
, 
Leypoldt, F.
, 
Paul, F.
, &amp; 
Friese, M. A.
 (2019). Sex differences in autoimmune disorders of the central nervous system. Seminars in Immunopathology, 41(2), 177–188. 10.1007/s00281-018-0723-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00281-018-0723-8</ArticleId>
            <ArticleId IdType="pubmed">30361800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jacob, A.
, 
Matiello, M.
, 
Wingerchuk, D. M.
, 
Lucchinetti, C. F.
, 
Pittock, S. J.
, &amp; 
Weinshenker, B. G.
 (2007). Neuromyelitis optica: Changing concepts. Journal of Neuroimmunology, 187(1–2), 126–138. 10.1016/j.jneuroim.2007.04.009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2007.04.009</ArticleId>
            <ArticleId IdType="pubmed">17512987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jarius, S.
, 
Aboul‐Enein, F.
, 
Waters, P.
, 
Kuenz, B.
, 
Hauser, A.
, 
Berger, T.
, … 
Kristoferitsch, W.
 (2008). Antibody to aquaporin‐4 in the long‐term course of neuromyelitis optica. Brain, 131(Pt 11), 3072–3080. 10.1093/brain/awn240
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awn240</ArticleId>
            <ArticleId IdType="pmc">PMC2577801</ArticleId>
            <ArticleId IdType="pubmed">18945724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jarius, S.
, 
Franciotta, D.
, 
Paul, F.
, 
Ruprecht, K.
, 
Bergamaschi, R.
, 
Rommer, P. S.
, … 
Wildemann, B.
 (2010). Cerebrospinal fluid antibodies to aquaporin‐4 in neuromyelitis optica and related disorders: Frequency, origin, and diagnostic relevance. Journal of Neuroinflammation, 7, 52
10.1186/1742-2094-7-52
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-7-52</ArticleId>
            <ArticleId IdType="pmc">PMC2945323</ArticleId>
            <ArticleId IdType="pubmed">20825655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jarius, S.
, 
Kleiter, I.
, 
Ruprecht, K.
, 
Asgari, N.
, 
Pitarokoili, K.
, 
Borisow, N.
, … 
Wildemann, B.
 (2016). MOG‐IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement—frequency, presentation and outcome. Journal of Neuroinflammation, 13(1), 10.1186/s12974-016-0719-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0719-z</ArticleId>
            <ArticleId IdType="pmc">PMC5088671</ArticleId>
            <ArticleId IdType="pubmed">27802825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jarius, S.
, 
Paul, F.
, 
Aktas, O.
, 
Asgari, N.
, 
Dale, R. C.
, 
de Seze, J.
, … 
Wildemann, B.
 (2018). MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. Journal of Neuroinflammation, 15(1), 134
10.1186/s12974-018-1144-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-018-1144-2</ArticleId>
            <ArticleId IdType="pmc">PMC5932838</ArticleId>
            <ArticleId IdType="pubmed">29724224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jarius, S.
, 
Paul, F.
, 
Fechner, K.
, 
Ruprecht, K.
, 
Kleiter, I.
, 
Franciotta, D.
, … 
Wildemann, B.
 (2014). Aquaporin‐4 antibody testing: Direct comparison of M1‐AQP4‐DNA‐transfected cells with leaky scanning versus M23‐AQP4‐DNA‐transfected cells as antigenic substrate. Journal of Neuroinflammation, 11, 129
10.1186/1742-2094-11-129
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-11-129</ArticleId>
            <ArticleId IdType="pmc">PMC4128531</ArticleId>
            <ArticleId IdType="pubmed">25074611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jarius, S.
, 
Paul, F.
, 
Franciotta, D.
, 
Ruprecht, K.
, 
Ringelstein, M.
, 
Bergamaschi, R.
, … 
Wildemann, B.
 (2011). Cerebrospinal fluid findings in aquaporin‐4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. Journal of the Neurological Sciences, 306(1–2), 82–90. 10.1016/j.jns.2011.03.038
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2011.03.038</ArticleId>
            <ArticleId IdType="pubmed">21550068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jarius, S.
, 
Ruprecht, K.
, 
Kleiter, I.
, 
Borisow, N.
, 
Asgari, N.
, 
Pitarokoili, K.
, … &amp; 
Wildemann, B.
 (2016a). MOG‐IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long‐term outcome. Journal of Neuroinflammation, 13(1), 10.1186/s12974-016-0718-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0718-0</ArticleId>
            <ArticleId IdType="pmc">PMC5086042</ArticleId>
            <ArticleId IdType="pubmed">27793206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jarius, S.
, 
Ruprecht, K.
, 
Kleiter, I.
, 
Borisow, N.
, 
Asgari, N.
, 
Pitarokoili, K.
, … &amp; 
Reindl, M.
 (2016b). MOG‐IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long‐term course, association with AQP4‐IgG, and origin. Journal of Neuroinflammation, 13(1), 10.1186/s12974-016-0717-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0717-1</ArticleId>
            <ArticleId IdType="pmc">PMC5084340</ArticleId>
            <ArticleId IdType="pubmed">27788675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Juryńczyk, M.
, 
Weinshenker, B.
, 
Akman‐Demir, G.
, 
Asgari, N.
, 
Barnes, D.
, 
Boggild, M.
, … 
Palace, J.
 (2016). Status of diagnostic approaches to AQP4‐IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 263(1), 140–149. 10.1007/s00415-015-7952-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-015-7952-8</ArticleId>
            <ArticleId IdType="pmc">PMC4816597</ArticleId>
            <ArticleId IdType="pubmed">26530512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kawachi, I.
, &amp; 
Lassmann, H.
 (2017). Neurodegeneration in multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 88(2), 137–145. 10.1136/jnnp-2016-313300
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2016-313300</ArticleId>
            <ArticleId IdType="pubmed">27671902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kessler, R. A.
, 
Mealy, M. A.
, 
Jimenez‐Arango, J. A.
, 
Quan, C.
, 
Paul, F.
, 
López, R.
, … 
Levy, M.
 (2017). Anti‐aquaporin‐4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. Multiple Sclerosis and Related Disorders, 17, 198–201. 10.1016/j.msard.2017.08.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2017.08.005</ArticleId>
            <ArticleId IdType="pubmed">29055457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kim, H. J.
, 
Paul, F.
, 
Lana‐Peixoto, M. A.
, 
Tenembaum, S.
, 
Asgari, N.
, 
Palace, J.
, … 
Kim, S.‐H.
 (2015). MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology, 84(11), 1165–1173. 10.1212/WNL.0000000000001367
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001367</ArticleId>
            <ArticleId IdType="pmc">PMC4371410</ArticleId>
            <ArticleId IdType="pubmed">25695963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kitley, J.
, 
Waters, P.
, 
Woodhall, M.
, 
Leite, M. I.
, 
Murchison, A.
, 
George, J.
, … 
Palace, J.
 (2014). Neuromyelitis optica spectrum disorders with aquaporin‐4 and myelin‐oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurology, 71(3), 276–283. 10.1001/jamaneurol.2013.5857
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.5857</ArticleId>
            <ArticleId IdType="pubmed">24425068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kleiter, I.
, 
Hellwig, K.
, 
Berthele, A.
, 
Kumpfel, T.
, 
Linker, R. A.
, Hartung H. P., … 
Aktas, O.
 (2012). Failure of natalizumab to prevent relapses in neuromyelitis optica. Archives of Neurology, 69(2), 239–245. 10.1001/archneurol.2011.216
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.216</ArticleId>
            <ArticleId IdType="pubmed">22332191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Koch‐Henriksen, N.
, 
Thygesen, L. C.
, 
Stenager, E.
, 
Laursen, B.
, &amp; 
Magyari, M.
 (2018). Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology, 90(22), e1954–e1963. 10.1212/WNL.0000000000005612
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000005612</ArticleId>
            <ArticleId IdType="pubmed">29720546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kremer, L.
, 
Mealy, M.
, 
Jacob, A.
, 
Nakashima, I.
, 
Cabre, P.
, 
Bigi, S.
, … 
de Seze, J.
 (2014). Brainstem manifestations in neuromyelitis optica: A multicenter study of 258 patients. Multiple Sclerosis Journal, 20(7), 843–847. 10.1177/1352458513507822
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458513507822</ArticleId>
            <ArticleId IdType="pubmed">24099751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Mader, S.
, 
Gredler, V.
, 
Schanda, K.
, 
Rostasy, K.
, 
Dujmovic, I.
, 
Pfaller, K.
, … 
Reindl, M.
 (2011). Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Journal of Neuroinflammation, 8, 184
10.1186/1742-2094-8-184
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-8-184</ArticleId>
            <ArticleId IdType="pmc">PMC3278385</ArticleId>
            <ArticleId IdType="pubmed">22204662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Matiello, M.
, 
Lennon, V. A.
, 
Jacob, A.
, 
Pittock, S. J.
, 
Lucchinetti, C. F.
, 
Wingerchuk, D. M.
, &amp; 
Weinshenker, B. G.
 (2008). NMO‐IgG predicts the outcome of recurrent optic neuritis. Neurology, 70(23), 2197–2200. 10.1212/01.wnl.0000303817.82134.da
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000303817.82134.da</ArticleId>
            <ArticleId IdType="pubmed">18434643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Mealy, M. A.
, 
Kim, S.‐H.
, 
Schmidt, F.
, 
López, R.
, 
Jimenez Arango, J. A.
, 
Paul, F.
, … 
Levy, M.
 (2018). Aquaporin‐4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 24(13), 1737–1742. 10.1177/1352458517730131
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458517730131</ArticleId>
            <ArticleId IdType="pmc">PMC5794637</ArticleId>
            <ArticleId IdType="pubmed">28857723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Melamed, E.
, 
Levy, M.
, 
Waters, P. J.
, 
Sato, D. K.
, 
Bennett, J. L.
, 
John, G. R.
, … &amp; 
Han, M. H.
 (2015). Update on biomarkers in neuromyelitis optica. Neurology—neuroimmunology Neuroinflammation, 2(4), e134
10.1212/NXI.0000000000000134
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000134</ArticleId>
            <ArticleId IdType="pmc">PMC4516398</ArticleId>
            <ArticleId IdType="pubmed">26236760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Mori, M.
, 
Kuwabara, S.
, &amp; 
Paul, F.
 (2018). Worldwide prevalence of neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 89(6), 555–556. 10.1136/jnnp-2017-317566
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2017-317566</ArticleId>
            <ArticleId IdType="pubmed">29436488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Oertel, F. C.
, 
Zimmermann, H.
, 
Paul, F.
, &amp; 
Brandt, A. U.
 (2018). Optical coherence tomography in neuromyelitis optica spectrum disorders: Potential advantages for individualized monitoring of progression and therapy. EPMA Journal, 9(1), 21–33. 10.1007/s13167-017-0123-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13167-017-0123-5</ArticleId>
            <ArticleId IdType="pmc">PMC5833887</ArticleId>
            <ArticleId IdType="pubmed">29515685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Pache, F.
, 
Zimmermann, H.
, 
Mikolajczak, J.
, 
Schumacher, S.
, 
Lacheta, A.
, 
Oertel, F. C.
, … &amp; 
Brandt, A. U.
 (2016). MOG‐IgG in NMO and related disorders: A multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG‐IgG‐seropositive versus AQP4‐IgG‐seropositive patients. Journal of Neuroinflammation, 13(1), 10.1186/s12974-016-0720-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0720-6</ArticleId>
            <ArticleId IdType="pmc">PMC5088645</ArticleId>
            <ArticleId IdType="pubmed">27802824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Pandit, L.
, 
Asgari, N.
, 
Apiwattanakul, M.
, 
Palace, J.
, 
Paul, F.
, 
Leite, M. I.
, … 
Chitnis, T.
 (2015). Demographic and clinical features of neuromyelitis optica: A review. Multiple Sclerosis Journal, 21(7), 845–853. 10.1177/1352458515572406
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458515572406</ArticleId>
            <ArticleId IdType="pmc">PMC4463026</ArticleId>
            <ArticleId IdType="pubmed">25921037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Papp, V.
, 
Illes, Z.
, 
Magyari, M.
, 
Koch‐Henriksen, N.
, 
Kant, M.
, 
Pfleger, C. C.
, … 
Petersen, T.
 (2018). Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology, 10.1212/WNL.0000000000006645
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006645</ArticleId>
            <ArticleId IdType="pmc">PMC6329324</ArticleId>
            <ArticleId IdType="pubmed">30413632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Sato, D. K.
, 
Callegaro, D.
, 
Lana‐Peixoto, M. A.
, 
Waters, P. J.
, 
Jorge, F. M. D. H.
, 
Takahashi, T.
, … 
Fujihara, K.
 (2014). Distinction between MOG antibody‐positive and AQP4 antibody‐positive NMO spectrum disorders. Neurology, 82(6), 474–481. 10.1212/WNL.0000000000000101
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000101</ArticleId>
            <ArticleId IdType="pmc">PMC3937859</ArticleId>
            <ArticleId IdType="pubmed">24415568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Sechi, E.
, &amp; 
Flanagan, E. P.
 (2019). Area postrema syndrome in autoimmune GFAP astrocytopathy. Multiple Sclerosis Journal, 135245851982648
10.1177/1352458519826489
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458519826489</ArticleId>
            <ArticleId IdType="pubmed">30663500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Soelberg, K.
, 
Jarius, S.
, 
Skejoe, H.
, 
Engberg, H.
, 
Mehlsen, J. J.
, 
Nilsson, A. C.
, … 
Asgari, N.
 (2017). A population‐based prospective study of optic neuritis. Multiple Sclerosis Journal, 23(14), 1893–1901. 10.1177/1352458517734070
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458517734070</ArticleId>
            <ArticleId IdType="pubmed">28980518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Trebst, C.
, 
Jarius, S.
, 
Berthele, A.
, 
Paul, F.
, 
Schippling, S.
, 
Wildemann, B.
, … 
Kümpfel, T.
 (2014). Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology, 261(1), 1–16. 10.1007/s00415-013-7169-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-7169-7</ArticleId>
            <ArticleId IdType="pmc">PMC3895189</ArticleId>
            <ArticleId IdType="pubmed">24272588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Waters, P. J.
, 
Pittock, S. J.
, 
Bennett, J. L.
, 
Jarius, S.
, 
Weinshenker, B. G.
, &amp; 
Wingerchuk, D. M.
 (2014). Evaluation of aquaporin‐4 antibody assays. Clinical and Experimental Neuroimmunology, 5(3), 290–303. 10.1111/cen3.12107
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen3.12107</ArticleId>
            <ArticleId IdType="pmc">PMC5102503</ArticleId>
            <ArticleId IdType="pubmed">27840658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Waters, P.
, 
Reindl, M.
, 
Saiz, A.
, 
Schanda, K.
, 
Tuller, F.
, 
Kral, V.
, … 
Marignier, R.
 (2016). Multicentre comparison of a diagnostic assay: Aquaporin‐4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 87(9), 1005–1015. 10.1136/jnnp-2015-312601
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2015-312601</ArticleId>
            <ArticleId IdType="pmc">PMC5013123</ArticleId>
            <ArticleId IdType="pubmed">27113605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Weinshenker, B. G.
, &amp; 
Wingerchuk, D. M.
 (2017). Neuromyelitis spectrum disorders. Mayo Clinic Proceedings, 92(4), 663–679. 10.1016/j.mayocp.2016.12.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2016.12.014</ArticleId>
            <ArticleId IdType="pubmed">28385199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Wingerchuk, D. M.
, 
Banwell, B.
, 
Bennett, J. L.
, 
Cabre, P.
, 
Carroll, W.
, 
Chitnis, T.
, … 
Weinshenker, B. G.
 (2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2), 177–189. 10.1212/wnl.0000000000001729
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.0000000000001729</ArticleId>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Wingerchuk, D. M.
, 
Hogancamp, W. F.
, 
O'Brien, P. C.
, &amp; 
Weinshenker, B. G.
 (1999). The clinical course of neuromyelitis optica (Devic's syndrome). Neurology, 53(5), 1107–1107. 10.1212/WNL.53.5.1107
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.53.5.1107</ArticleId>
            <ArticleId IdType="pubmed">10496275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Wingerchuk, D. M.
, 
Lennon, V. A.
, 
Lucchinetti, C. F.
, 
Pittock, S. J.
, &amp; 
Weinshenker, B. G.
 (2007). The spectrum of neuromyelitis optica. The Lancet Neurology, 6(9), 805–815. 10.1016/s1474-4422(07)70216-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1474-4422(07)70216-8</ArticleId>
            <ArticleId IdType="pubmed">17706564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Wingerchuk, D. M.
, 
Lennon, V. A.
, 
Pittock, S. J.
, 
Lucchinetti, C. F.
, &amp; 
Weinshenker, B. G.
 (2006). Revised diagnostic criteria for neuromyelitis optica. Neurology, 66(10), 1485–1489. 10.1212/01.wnl.0000216139.44259.74
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000216139.44259.74</ArticleId>
            <ArticleId IdType="pubmed">16717206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Zekeridou, A.
, &amp; 
Lennon, V. A.
 (2015). Aquaporin‐4 autoimmunity. Neurology—neuroimmunology Neuroinflammation, 2(4), e110
10.1212/NXI.0000000000000110
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000110</ArticleId>
            <ArticleId IdType="pmc">PMC4442096</ArticleId>
            <ArticleId IdType="pubmed">26185772</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
